BSP supported article, Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost Savings, published in PharmacoEconomics – Open journal

(Boston,  September 2017) – Boston Strategic Partners supported Baxter in the creation an article recently published in PharmacoEconomics – Open journal. The article titled “Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost Savings” is an  analysis evaluating the economic impact of increasing usage of a calcium-free balanced crystalloid solution (BAL) in patients with systemic inflammatory response syndrome (SIRS) on an annual hospital budget.

An Excel®-based economic model was developed to estimate costs associated with increased BAL usage (i.e., use in a greater proportion of patients), from the US hospital perspective, over a 5-year time horizon. Clinical inputs were based on the results of a retrospective Electronic Health Record (EHR) database analysis identifying significantly fewer complications among SIRS patients receiving predominantly BAL versus saline. Complication-associated costs, adjusted to 2015, were obtained from published reports. Scenario analyses examined cost impacts for hospitals of various sizes, with different BAL adoption levels and rates.

Link to the article:

About BSP
Founded in 2003, Boston Strategic Partners, Inc. is a dedicated healthcare and life sciences company. We offer five different types of services:

For more information or to schedule a meeting with our team, please email us at

About Baxter International

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries.